The amount of circulating DNA and the presence of TP53 mutations in plasma predict clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs
Published in 2022 by
M. Del Re,
S. Crucitta,
F. Paolieri,
F. Cucchiara 
,
E. Verzoni,
F. Bloise,
R. Ciampi,
C. Mercinelli,
A. Capuano,
L. Sportiello,
A. Martinetti,
G. Procopio,
L. Galli,
C. Porta,
S. Bracarda
and other authors.
,
E. Verzoni,
F. Bloise,
R. Ciampi,
C. Mercinelli,
A. Capuano,
L. Sportiello,
A. Martinetti,
G. Procopio,
L. Galli,
C. Porta,
S. Bracarda
and other authors.
